EXELHealthcare · Biotechnology

EXEL Stock Forecast: Exelixis, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026

$56

−2.28% on the day

The 19 Wall Street analysts covering Exelixis, Inc. hold a median 12-month price target of $53 — -6.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 12 Sept 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap

$13.9B

Ticker Nerd rank

98 / 100

Median analyst target

$53

Analysts covering

Revenue$628.7M+10.6% y/y

Operating income$248.4M

Net income$212.1M

Free cash flow$298.4M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−5.1%

+9.3%

YTD

+28.0%

+43.6%

From 52W high

−5.1%

From 52W low

+62.5%

$35

$59

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

EXEL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Exelixis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026

98 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value

100

Quality

Volatility

Issuance

Accruals

Momentum

Growth

Revisions

Size

Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Revisions (54): Analysts have, on balance, been cutting their forecasts.

Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

EXEL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EXEL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says19 analysts

7 Buy11 Hold1 Sell

Low $41Median $53High $66

The green dot is the last close — the median target sits −6.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.

Date	Firm	Action	Rating	Target
19 Aug 2026	BMO Capital	Initiates	Market Perform	$54
6 Aug 2026	Stifel	Maintains	Hold	$47 → $51
6 Aug 2026	Stifel	Maintains	Hold	—
6 Aug 2026	Truist Securities	Maintains	Hold	—
6 Aug 2026	Truist Securities	Maintains	Hold	$56 → $52
23 July 2026	Morgan Stanley	Maintains	Equal-Weight	$50 → $53
23 July 2026	Morgan Stanley	Maintains	Equal-Weight	—
14 July 2026	Barclays	Maintains	Equal-Weight	$45 → $49
14 July 2026	Barclays	Maintains	Equal-Weight	—
13 July 2026	Wells Fargo	Maintains	Equal-Weight	—
13 July 2026	Wells Fargo	Maintains	Equal-Weight	$40 → $49
7 July 2026	RBC Capital	Maintains	Sector Perform	—
7 July 2026	RBC Capital	Maintains	Sector Perform	$43 → $46
7 July 2026	Truist Securities	Maintains	Hold	$54 → $56
7 July 2026	Truist Securities	Maintains	Hold	—
2 July 2026	HC Wainwright & Co.	Reiterates	Buy	—
2 July 2026	UBS	Maintains	Neutral	—
25 June 2026	Truist Securities	Downgrade	Hold	—
24 June 2026	Citizens	Maintains	Market Outperform	—
7 May 2026	HC Wainwright & Co.	Maintains	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EXEL appears on the weeks it earns a place.

Performance

EXEL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Exelixis, Inc. returned +43.6% against +17.5% for the S&P 500, dividends included.

EXEL vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

EXEL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

EPS revision, 90 days

+0.7%

Analysts raising

Analysts cutting

Fundamentals

Exelixis, Inc. (EXEL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 17.6×
Price / sales: 5.7×
Price / book: 7.6×
EV / EBITDA: 13.0×

Growth & margins

Revenue growth (YoY): 10.6%
Earnings growth (YoY): 14.7%
Gross margin: 96.7%
Operating margin: 39.5%
Net margin: 35.3%

Returns & dividend

Return on equity: 44.4%
Return on assets: 24.0%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Exelixis, Inc. (EXEL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Exelixis, Inc. has a market value of $13.9B and an enterprise value of $13.2B.
Revenue in the twelve months to 30 June 2026: $2.4B. The latest quarter grew 10.6% year on year.
Net income over the same four quarters: $860.6M, a 35.3% net margin.
Diluted earnings per share, trailing twelve months: $3.18.
Free cash flow in the twelve months to 30 June 2026: $1.2B.
Exelixis, Inc. spent $1.1B on share buybacks in the twelve months to 30 June 2026.
Shares outstanding: 248.9M.
Trailing P/E: 17.6×; forward P/E: 13.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Exelixis, Inc. employs 1,077 people — $2.3M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

EXEL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
EXELExelixis, Inc.	$13.9B	98
BBIOBridgeBio Pharma, Inc.	$14.0B	68
SMMTSummit Therapeutics, Inc.	$14.0B	21
JAZZJazz Pharmaceuticals Plc	$15.4B	99
BMRNBioMarin Pharmaceutical, Inc.	$12.7B	64
MDGLMadrigal Pharmaceuticals, Inc.	$12.3B	69
HALOHalozyme Therapeutics, Inc.	$12.2B	97

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Exelixis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EXEL news & analysis

Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises

MarketBeat · 14 Sept 2026positive

Exelixis executives outlined a franchise-focused growth strategy centered on expanding CABOMETYX across renal cell carcinoma and neuroendocrine tumors while advancing zanzalintinib through multiple late-stage studies.

Why it matters — Exelixis watchers would care because the company is signaling pipeline and label-expansion momentum across two key drug programs that could shape its future growth.

Exelixis: The FDA Delay Costs Less Than The Market Thinks

Seeking Alpha · 14 Sept 2026neutral

The FDA extended its review of Exelixis' zanzalintinib by three months, with no new clinical failure or safety signal disclosed. The report notes that CABOMETYX continues growing and that 2026 guidance includes no zanzalintinib launch revenue, arguing the delay reduces the asset's value by only a small amount.

Why it matters — Exelixis watchers would care because the three-month extension of zanzalintinib's FDA review—with no disclosed clinical or safety issues—may have a smaller impact on the asset's value than the initial market reaction suggested.

Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In

Benzinga · 11 Sept 2026negative

The FDA extended the review period for Exelixis's new drug application for zanzalintinib in combination with atezolizumab for metastatic colorectal cancer by three months, which was announced on Friday. The delay caused Exelixis stock to slip, and an analyst weighed in on the news.

Why it matters — A three-month extension in the FDA review period delays the potential approval timeline for a key pipeline drug in Exelixis's colorectal cancer program, matters for investors tracking the company's regulatory progress.

U.S. FDA extends review of Exelixis' cancer drug

Reuters · 11 Sept 2026neutral

The U.S. Food and Drug Administration has extended its review of Exelixis' experimental colorectal cancer drug combination by three months, according to a company filing on Friday.

Why it matters — A delay in the FDA review timeline affects when Exelixis' experimental colorectal cancer combination could potentially reach the market.

Exelixis, Inc. (EXEL) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha · 9 Sept 2026neutral

Exelixis, Inc. presented at Citigroup's Biopharma Back to School Summit 2026, with a transcript of the event published on Seeking Alpha. The presentation featured the company's remarks at the industry conference.

Why it matters — EXEL watchers would care because the presentation provides insight into the company's message and positioning delivered directly to investors and analysts at a major industry conference.

FAQ

Frequently asked questions about EXEL stock

What is the EXEL stock price forecast for 2026-2027?

The 19 Wall Street analysts covering Exelixis, Inc. have a median 12-month price target of $53, with estimates ranging from $41 to $66. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EXEL stock a buy right now?

Of the 19 analysts covering Exelixis, Inc., 7 rate it a Buy, 11 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Exelixis, Inc. 98 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EXEL?

As at 12 Sept 2026, Exelixis, Inc. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).

Will EXEL stock go up?

No one can know that. What the data says: the median 12-month target from 19 analysts implies -6.5% from the last close, and Ticker Nerd's factor model ranks Exelixis, Inc. 98 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EXEL stock forecast for 2030?

No analyst covering Exelixis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EXEL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $41 to $66 over the next 12 months.

How has EXEL stock performed over the past year?

Exelixis, Inc. returned +43.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Exelixis, Inc. do?

Exelixis Inc. is an oncology-focused biopharmaceutical company that discovers, develops, and commercializes medicines for difficult-to-treat cancers.

What is the latest news on EXEL?

The most recent item we track (MarketBeat, 14 Sept 2026): "Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises". Exelixis executives outlined a franchise-focused growth strategy centered on expanding CABOMETYX across renal cell carcinoma and neuroendocrine tumors while advancing zanzalintinib through multiple late-stage studies.

Company

About Exelixis, Inc.

Exelixis Inc. is an oncology-focused biopharmaceutical company that discovers, develops, and commercializes medicines for difficult-to-treat cancers. The company’s current portfolio centers on cancer therapies built around cabozantinib, including CABOMETYX and COMETRIQ, which are used across multiple tumor types in clinical practice. Exelixis also advances a broader pipeline of small-molecule and biotherapeutic candidates aimed at expanding treatment options in solid tumors and other oncology settings. In addition to internal drug development, the company works through collaborations to support research, development, and commercialization activities. Based in Alameda, California, Exelixis plays a significant role in the cancer treatment market by combining approved products with an active development pipeline focused on targeted oncology medicines.

CEO Dr. Michael M. Morrissey Ph.D. · 1,077 employees · United States · https://www.exelixis.com